Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23467369 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL25010861 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL15764178 | 0.94 | GRN (0.44) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL19371886 | 0.82 | GRN (0.51) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL421252 | 0.82 | GRN (0.51) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL11796323 | 0.82 | GRN (0.51) | GRNSORT1CPB2LTA4H | |
| SCHEMBL11796335 | 0.82 | GRN (0.51) | GRNSORT1CPB2LTA4H | |
| SCHEMBL8225317 | 0.81 | GRN (0.57) | GRNSORT1CPB2LTA4HMME | |
| SCHEMBL805198 | 0.81 | GRN (0.50) | GRNSORT1CPB2LTA4H | |
| SCHEMBL7566961 | 0.81 | GRN (0.50) | GRNSORT1CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247747-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MCHR2 | GRN 3113/4885SORT1 1200/4885CPB2 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.